Industry Context — Common BS Fingerprints in Medical Devices, Pharma & Biotech
Amgen (KANJINTI)
(https://kanjinti.com) 📸 Data Snapshot: May 31, 2026Analyze the raw signals below. How would a machine score this business’s credibility?
Here are the exact signals captured from up to six pages of the site — the same raw inputs the evaluation engine analyzed. They are grouped by signal type so you can weigh each the way the machine does.
🏗️ Semantic Structure — heading hierarchy & page identity (Info Density · Commodity Fingerprint)
HOMEPAGE Herceptin® Biosimilar | KANJINTI® (trastuzumab-anns) for HCPs (https://kanjinti.com)
Herceptin® Biosimilar | KANJINTI® (trastuzumab-anns) for HCPs
Find out more about KANJINTI® (trastuzumab-anns), a Herceptin® biosimilar. See Important Safety Information including Boxed Warning.
NAV_HEADER_REPEATED What is KANJINTI® | KANJINTI® (trastuzumab-anns) (https://kanjinti.com/patient-resources/what-is-kanjinti/)
What is KANJINTI® | KANJINTI® (trastuzumab-anns)
Learn more about KANJINTI® (trastuzumab-anns), a Herceptin® biosimilar. See Important Safety and Prescribing Info, including Boxed Warning.
NAV_HEADER_REPEATED_BODY Amgen Biosimilars | KANJINTI® (trastuzumab-anns) for HCPs (https://kanjinti.com/hcp/biosimilar-expertise/)
Amgen Biosimilars | KANJINTI® (trastuzumab-anns) for HCPs
Find out how Amgen continues to be dedicated to oncology treatment and care, backed by 40 years of experience in biologics. See Important Safety Info, including Boxed Warning.
NAV_HEADER_REPEATED Dosing Schedule | KANJINTI® (trastuzumab-anns) for HCPs (https://kanjinti.com/hcp/dosing/)
Dosing Schedule | KANJINTI® (trastuzumab-anns) for HCPs
Discover KANJINTI® (trastuzumab-anns), which has identical dosing to Herceptin® IV. See Important Safety Info, including Boxed Warning.
📝 The Narrative — clean text per page (Info Density · Semantic Coherence)
HOMEPAGE (https://kanjinti.com) Herceptin® Biosimilar | KANJINTI® (trastuzumab-anns) for HCPs
[IMG: KANJINTI® (trastuzumab-anns) For Injection] *As of [June 30, 2025]. Number of non-oncology patients calculated from duration of therapy and adherence data from IQVIA Analytics Link and IQVIA Patient Link, respectively. Number of oncology patients determined using claims data (US) and physician surveys (ex-US). Patient count estimates may not accurately reflect the actual number of patients treated with Amgen biosimilars if adherence or length of treatment in real world differs from the assumptions used. KANJINTI® is indicated for the treatment of:2 HER2-overexpressing breast cancer HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma KANJINTI® SETS A RIGOROUS STANDARD FOR HERCEPTIN® BIOSIMILARITY [IMG: The first and only Herceptin® biosimilar with single-transition study data in the eBC setting] FDA approved with highly similar safety and efficacy to Herceptin®, with no clinically meaningful differences.2,3 [IMG: btn-medi_rainbow-svg] totality of evidence [IMG: Comprehensive support for you and your patients] Comprehensive support for you and your patients [IMG: btn-medi_rainbow-svg] support [IMG: same support] Amgen has an incredible track record of reliable supply.4 [IMG: btn-medi_rainbow-svg] biosimilar expertise Backed by Amgen Expertise 40+ Years experience in biologics [IMG: btn-medi_rainbow-svg] biosimilar expertise HER2 = human epidermal growth factor receptor 2; IV = intravenous. [IMG: AMGEN® Biosimilars] Get the story behind Amgen's commitment to biosimilars.Amgen Biosimilars × Amgen stands with our local Los Angeles community. Click here to learn what we are doing to support and contact us if the fires have impacted your access to Amgen medication.
SUB-PAGE (https://kanjinti.com/patient-resources/what-is-kanjinti/) What is KANJINTI® | KANJINTI® (trastuzumab-anns)
For Patients/ What Is KANJINTI® What is KANJINTI® Why Amgen Biosimilars Support About her2+ Cancer [H2] There is treatment for your HER2 positive (HER2+) breast OR GASTRIC cancer—and it is called KANJINTI®1 [H3] KANJINTI® IS: Approved by the FDA (Food and Drug Administration) for HER2+ breast and gastric cancer. KANJINTI® is also known by its chemical name, trastuzumab-anns (trast-OO-zoo-mab).1 A biologic, which is a drug made from a living cell. Biologic medicines are used to treat many conditions.1,2 [H3] KANJINTI® WORKS WITH YOUR BODY'S IMMUNE SYSTEM TO Help FIGHT CANCER CELLS3 1 [H6] KANJINTI® attaches to HER2 receptors on cells.3 [IMG: How does KANJINTI™ work?] [H6] NORMAL CELL Normal cells have some HER2 receptors.4 2 [H6] THIS PREVENTS cancer cells from growing and multiplying.3,* * Because normal cells have HER2 receptors, KANJINTI® can also prevent their growth and cause serious side effects. [IMG: How does KANJINTI™ work?] [H6] HER2+ CANCER CELL HER2+ cancer cells have many more HER2 receptors than normal cells.4 3 [H6] the cancer cell is then destroyed by the body's defenses.3 [IMG: How does KANJINTI™ work?] [H6] HER2+ CANCER CELL [IMG: First KANJINTI] KANJINTI®® [H2] WhY KANJINTI®? [H3] PROVEN TO BE AS EFFECTIVE AS HERCEPTIN® KANJINTI® is a biosimilar to the cancer drug Herceptin® and is FDA-approved for the same uses. KANJINTI® has been tested worldwide and has been proven to have similar side effects as Herceptin®.1,5 [H3] CAN I BE GIVEN KANJINTI® IF I'VE ALREADY STARTED WITH HERCEPTIN®? [IMG: single transition] [IMG: single transition] [H3] CAN I BE GIVEN KANJINTI® IF I'VE ALREADY STARTED WITH HERCEPTIN®? KANJINTI® has been proven to be as effective as Herceptin® in a study. Some patients in this study started treatment with Herceptin®, then were transitioned to KANJINTI® for the rest of the study to make sure the side effects were similar compared with patients who only took KANJINTI® for the length of the study.5 [IMG: Proven similar to Herceptin] [IMG: Clinically studied with patients worldwide] [H3] A few things to keep in mind as you start KANJINTI® Now that you know more about HER2+ breast and gastric cancer and KANJINTI®, you may have some questions about starting this course of therapy. [IMG: How is KANJINTI® Prescribed?] [H2] KANJINTI® may be prescribed alone or with chemotherapy.1 Your doctor may choose to use KANJINTI® with or without chemotherapy. Your doctor or nurse will discuss which combination of treatments is right for you. [IMG: KANJINTI® Infusion] [H2] KANJINTI® is given through an infusion.1 You will receive KANJINTI® either once a week or once every 3 weeks for as long as your doctor thinks it is working for you and as long as you are not having any serious side effects.1 The points above offer only an outline of what you might expect when starting KANJINTI®. Your doctor will make these treatment decisions with you. If your treatment plan is not clear, please talk with your treatment team. [H2] REGULAR HEART MONITORING IS IMPORTANT1 Per standard treatment with KANJINTI®, and similar drugs like Herceptin®, you will receive regular heart function checkups. These checkups occur throughout the course of your treatment.1 Heart function will be tested with an ECHO or MUGA scan.1 An ECHO scan is an ultrasound image of the heart. A MUGA scan takes a moving picture of your heart pumping blood.6 [IMG: KANJINTI® and Heart Monitoring] BEFORE Starting KANJINTI® every 3–4 MONTHS During & upon completion of KANJINTI® TReatment every 6 MONTHS for at least 2 years after completing KANJINTI® therapy [IMG: KANJINTI® and Heart Monitoring] ECHO = electrocardiogram; HER2 = human epidermal growth factor receptor 2; MUGA = multigated blood-pool imaging. [H2] What to look out for You should tell your doctor or nurse as soon as possible if you feel unwell or develop the following:1 Breathlessness and cough Swelling in your ankles/legs or face Feeling your heart flutter or an irregular heartbeat Weight gain of more than 5 pounds in 24 hours Dizziness or loss of consciousness Be sure to review the Important Safety Information to learn more about potential side effects and symptoms you need to watch for to help your doctor know when you are having a side effect × Amgen stands with our local Los Angeles community. Click here to learn what we are doing to support and contact us if the fires have impacted your access to Amgen medication.
SUB-PAGE (https://kanjinti.com/hcp/biosimilar-expertise/) Amgen Biosimilars | KANJINTI® (trastuzumab-anns) for HCPs
Amgen is a leader in biologics with a growing portfolio of biosimilars. [H2] HERITAGE [H4] The healthcare community has been able to trust us for decades [IMG: AMGEN Biologics – over 40 years of experience] [IMG: AMGEN Biologics – over 40 years of experience] [IMG: AMGEN Biologics – over 40 years of experience] AT AMGEN, WE’RE COMMITTED TO DELIVERING QUALITY PRODUCTS TO EVERY PATIENT, EVERY TIME [H2] EXPERTISE [H4] Real-world experience and expertise paved the way for our leadership in biosimilars [IMG: Over 300 Quality Checks During Manufacturing] [IMG: Over 300 Quality Checks During Manufacturing] *Available biosimilars across all global markets. †As of [June 30, 2025]. Number of non-oncology patients calculated from duration of therapy and adherence data from IQVIA Analytics Link and IQVIA Patient Link, respectively. Number of oncology patients determined using claims data (US) and physician surveys (ex-US). Patient count estimates may not accurately reflect the actual number of patients treated with Amgen biosimilars if adherence or length of treatment in real world differs from the assumptions used. [H2] Commitment [H4] WE ARE A LONG-STANDING BIOTECHNOLOGY LEADER COMMITTED TO DEVELOPING THE BIOSIMILAR MARKETPLACE Invested in the development of biosimilars and novel therapeutics [IMG: In the last decade, AMGEN® has achieved zero supply shortages] [IMG: In the last decade, AMGEN® has achieved zero supply shortages] [H2] Support [H4] WE ARE COMMITTED TO PROVIDING SOLUTION-ORIENTED RESOURCES THAT CAN HELP PROVIDE POSITIVE BIOSIMILAR EXPERIENCES [IMG: Amgen Support] [IMG: Amgen Support] [IMG: AMGEN® Biosimilars] Learn more about Amgen’s commitment to biosimilars.Amgen Biosimilars Learn how Amgen uses the same support programs for KANJINTI® as we do for our innovative treatments. [IMG: btn-medi_rainbow-svg] support [IMG: amgen-oncology_logo] To stay up-to-date on Amgen’s advances in oncology, visit AmgenOncology.com.Amgen Biosimilars × Amgen stands with our local Los Angeles community. Click here to learn what we are doing to support and contact us if the fires have impacted your access to Amgen medication.
SUB-PAGE (https://kanjinti.com/hcp/dosing/) Dosing Schedule | KANJINTI® (trastuzumab-anns) for HCPs
KANJINTI® PROVIDES IDENTICAL DOSING TO HERCEPTIN® IV ACROSS ALL INDICATIONS Dosing similarity is one of several ways Amgen helps provide you and your patients with a seamless experience.1,2 [IMG: kanjinti dosing with paclitaxel or docetaxel for adjuvant treatment] [IMG: kanjinti dosing with docetaxel and carboplatin for adjuvant treatment] [IMG: kanjinti dosing as single agent for adjuvant treatment] [IMG: kanjinti dosing as single agent or with paclitaxel for breast cancer] [IMG: kanjinti dosing as single agent or for gastric cancer] [IMG: kanjinti dosing with paclitaxel or docetaxel for adjuvant treatment] [IMG: kanjinti dosing with docetaxel and carboplatin for adjuvant treatment] [IMG: kanjinti dosing as single agent for adjuvant treatment] [IMG: kanjinti dosing as single agent or with paclitaxel for breast cancer] [IMG: kanjinti dosing as single agent or for gastric cancer] IV = intravenous; QW = once a week; Q3W = once every 3 weeks. Please refer to accompanying full Prescribing Information for complete dosing and administration guidelines. [IMG: 1M+ Patients] [IMG: Available 150 mg and 420 mg vials] [IMG: KANJINTI® 150mg and 420 mg vials] IV = intravenous; QW = once a week; Q3W = once every 3 weeks. Please refer to accompanying full Prescribing Information for complete dosing and administration guidelines. KANJINTI® has the same dosing as Herceptin® IV across all indications1,2 *Within 3 weeks following completion lof all chemotherapy. †EU-sourced Herceptin® was used in the LILAC study. The KANJINTI® clinical pharmacokinetic (PK) study demonstrated equivalence between EU- and US-sourced Herceptin® and KANJINTI®. See how KANJINTI® is proven biosimilar to Herceptin®.† [IMG: btn-medi_rainbow-svg] totality of evidence *Within 3 weeks following completion of all chemotherapy. †EU-sourced Herceptin® was used in the LILAC study. The KANJINTI® clinical pharmacokinetic (PK) study demonstrated equivalence between EU- and US-sourced Herceptin® and KANJINTI®. × Amgen stands with our local Los Angeles community. Click here to learn what we are doing to support and contact us if the fires have impacted your access to Amgen medication.
🛡️ Trust Signals — reviews, proof links, trust-theatre flag (Trust & Proof)
| Page | Reviews | Proof links |
|---|---|---|
| / (home) | 0 | 0 |
| /patient-resources/what-is-kanjinti/ | 1 | 0 |
| /hcp/biosimilar-expertise/ | 0 | 0 |
| /hcp/dosing/ | 0 | 0 |
🔗 Identity & Technical Layer — schema JSON-LD: identity chains, entity gaps (Identity & Authority)
Your Diagnosis
Before revealing the machine’s verdict, predict the BS score for each signal. Higher = more BS (more fluff, less verifiable substance). Drag each slider, then submit to compare your judgment against the engine.
Stuck? Reveal the heuristic lens — how the deterministic page-auditor reads each signal (no AI, pure pattern rules)
These are the structural rules a local, deterministic auditor applies — the same lens you can use to judge each signal. They describe what to look for, not this company’s result.
Classify each sentence as substantive or hollow. Grounding markers — numbers, currencies, dates, technical units, named entities — outweigh marketing adjectives. When fluff sits right next to hard evidence, the fluff is forgiven.
Pull the main entities out of the H1, then check whether they actually recur through the body. A page that announces one thing and then talks about another drifts. Headings with no real sentences underneath read as pseudo-substance.
Count trust words (review, testimonial, rating, verified) against real outbound proof links (Google, Trustpilot, Clutch, G2, Yelp). Lots of trust language with zero verification links is trust theatre. Unlinked logo galleries count against it.
Look at how much sentence length varies. Natural writing varies its rhythm; templated or mass-produced copy is statistically uniform. Very low variation reads as commodity content — unless unique named entities break the pattern.
Inspect the JSON-LD. Is there an Organization or Person schema, and does it carry sameAs links to real external profiles (LinkedIn, socials)? Missing schema or no identity declaration signals an anonymous entity.
Want to apply this lens yourself? The free BS Indicator Chrome extension runs these heuristic checks live on any page. Bear in mind it is a single-page, deterministic tool — it relies only on pattern rules for the page in front of it and does not perform the cross-page semantic correlation this audit uses, so its readout is a starting lens, not the full verdict.
Based on 784 businesses audited.
Medical Devices, Pharma & Biotech BS: Amgen (KANJINTI) (kanjinti.com)
KANJINTI avoids most corporate bullshit by leaning heavily on its regulatory ‘biosimilar’ status, which requires high-fidelity data. The BS detected is primarily ‘corporate polish’—generic headings and missing technical SEO identity markers (schema) rather than deceptive performance claims. It is a highly credible pharmaceutical resource with minor trust-theatre issues regarding review transparency.
Implement Organization and Physician/MedicalEntity JSON-LD schema to bridge the technical authority gap. Replace generic H2 headings like ‘Commitment’ and ‘Support’ with data-driven alternatives like ‘Global Supply Chain Metrics’ and ‘Patient Financial Assistance Outcomes.’ Provide direct outbound links to ClinicalTrials.gov for the LILAC study and other cited pharmacokinetic studies rather than relying on superscript footnoting. Remove the single unverified patient review to eliminate the trust theatre flag.
The site content perfectly aligns with the Pharma & Biotech category, focusing on biosimilarity, clinical trial equivalence (LILAC study), and FDA-approved indications. It adheres strictly to regulatory communication standards, including required Boxed Warnings and Important Safety Information (ISI).
“The score of 38 is driven primarily by technical omissions (Identity and Authority) and 'Trust Theatre' markers (unverified reviews/lack of outbound links). The site scored exceptionally well in Semantic Coherence, showing no drift between marketing promises and technical delivery. The Information Density score reflects a healthy balance of corporate branding and medical specifications.”
This training module utilizes a snapshot of public data from Amgen (KANJINTI), captured on May 31, 2026, to demonstrate how machine logic evaluates different types of business narratives.
Purpose: This data is presented under “Fair Use” / “Educational Exception” for the purpose of forensic semantic analysis, allowing users to compare human intuition against machine-generated evaluations.
Notice to Amgen (KANJINTI): This analysis is part of a non-adversarial audit conducted by 1 Euro SEO. The results provided by 1EuroSEO are intended as professional feedback to help improve any website’s machine-readability and authority signals. The 1EuroSEO BS Detection Tool is a free tool, and anyone can test any company to see how their content is interpreted by AI models.
Any company can use the insights for free and improve its voice by comparing it to industry clichés or competitors. When a company has updated its content, it can always submit a new audit request, which will be reflected in a new current score.
To all users: You are encouraged to visit the live site at https://kanjinti.com to view the most current version of its content and learn from the source what this company is about and what it offers.